Your browser doesn't support javascript.
loading
Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53-Aberrant Triple-Negative Breast Cancer.
Hu, Zhe-Yu; Zheng, Chanjuan; Yang, Jianbo; Ding, Siyu; Tian, Can; Xie, Ning; Xue, Lian; Wu, Muyao; Fu, Shujun; Rao, Zhouzhou; Price, Matthew A; McCarthy, James B; Ouyang, Quchang; Lin, Jizhen; Deng, Xiyun.
Affiliation
  • Hu ZY; Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya Medical School, Central South University, Changsha, China.
  • Zheng C; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha, China.
  • Yang J; Department of Breast Cancer Medical Oncology, the Affiliated Cancer Hospital of Xiangya Medical School, Central South University, Changsha, China.
  • Ding S; Key Laboratory of Model Animals and Stem Cell Biology in Hunan Province, Department of Pathophysiology, Hunan Normal University School of Medicine, Changsha, China.
  • Tian C; Key Laboratory of Translational Cancer Stem Cell Research, Hunan Normal University, Changsha, China.
  • Xie N; Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya Medical School, Central South University, Changsha, China.
  • Xue L; Department of Laboratory Medicine and Pathology and Comprehensive Cancer Center, University of Minnesota, Minneapolis, MN, United States.
  • Wu M; The Cancer Center, Union Hospital, Fujian Medical Center, Fuzhou, China.
  • Fu S; Key Laboratory of Model Animals and Stem Cell Biology in Hunan Province, Department of Pathophysiology, Hunan Normal University School of Medicine, Changsha, China.
  • Rao Z; Key Laboratory of Translational Cancer Stem Cell Research, Hunan Normal University, Changsha, China.
  • Price MA; Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya Medical School, Central South University, Changsha, China.
  • McCarthy JB; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha, China.
  • Ouyang Q; Department of Breast Cancer Medical Oncology, the Affiliated Cancer Hospital of Xiangya Medical School, Central South University, Changsha, China.
  • Lin J; Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya Medical School, Central South University, Changsha, China.
  • Deng X; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha, China.
Front Oncol ; 12: 804466, 2022.
Article de En | MEDLINE | ID: mdl-35280756
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies / Risk_factors_studies Langue: En Journal: Front Oncol Année: 2022 Type de document: Article Pays d'affiliation: Chine Pays de publication: Suisse
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies / Risk_factors_studies Langue: En Journal: Front Oncol Année: 2022 Type de document: Article Pays d'affiliation: Chine Pays de publication: Suisse